Clazakizumab for the Treatment of Chronic Active Antibody Mediated Rejection in Kidney Transplant Recipients

NCT03744910 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

194

Enrollment

INDUSTRY

Sponsor class

Stopped Early stop for lack of efficacy/futility (at Interim analysis)

Conditions

Antibody-mediated Rejection

Interventions

BIOLOGICAL: Clazakizumab
DRUG: Physiologic saline solution

Sponsor

CSL Behring

Collaborators

[object Object]